Status:
COMPLETED
Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.
Lead Sponsor:
Sanofi
Conditions:
Alzheimer Disease
Eligibility:
All Genders
50+ years
Phase:
PHASE1
PHASE2
Brief Summary
Primary: This study is being conducted to evaluate if AVE1625 is safe and tolerated in patients with Alzheimer's disease that is not too severe. There is also evaluation of whether patients who take t...
Eligibility Criteria
Inclusion
- The diagnosis of Alzheimer's disease
- Recent brain image(Computerized Axial Tomographic Scan -CAT scan or Magnetic Resonance Imaging - MRI)
- Mild to moderate range of disease; not too severe
Exclusion
- Severe or unstable medical diseases
- Neurological disorder other than Alzheimer's disease
- Depression that is not well controlled
- Treatment with memantine
- Inpatient in a total care facility (e.g.: Nursing home)
- Lack of reliable caregiver
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
162 Patients enrolled
Trial Details
Trial ID
NCT00380302
Start Date
September 1 2006
End Date
July 1 2007
Last Update
December 19 2008
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis Administrative Office
Bridgewater, New Jersey, United States, 08807
2
Sanofi-Aventis Administrative Office
Paris, France
3
Sanofi-Aventis Administrative Office
Milan, Italy
4
Sanofi-Aventis Administrative Office
Gouda, Netherlands